

Listing of the Claims:

1. - 66. (Canceled).

67. (New) A method for producing a plurality of dendritic cell/tumor cell hybrids capable of inducing a primary anti-tumor response specific to said tumor cell, said method comprising:

(i) fusing tumor cells to dendritic cells isolated from bone marrow, blood or lymph to produce a plurality of dendritic cell/tumor cell hybrids, wherein said dendritic cell is not a T-lymphocyte or B-lymphocyte,

(ii) selecting for dendritic cell/tumor cell hybrids which express tumor associated cell antigens of said tumor cell in association with a MHC Class II polypeptide,

thereby producing a plurality of dendritic cell/tumor cell hybrids capable of inducing a primary anti-tumor response specific to said tumor cell.

68. (New) The method of claim 67, wherein said dendritic cell/tumor cell hybrids further express ICAM, and/or B7.

69. (New) The method of claim 67, further comprising culturing said dendritic cell/tumor cell hybrids in vitro with GM-CSF, TNF α , IFN γ , or a combination thereof.

70. (New) The method of claim 67, wherein the anti-tumor response specific to said tumor cell is an in vivo anti-tumor response.

71. (New) The method of claim 70, wherein said in vivo anti-tumor response comprises an in vivo induction of immune effectors that confer resistance to a subsequent challenge with said tumor cell.

72. (New) The method of claim 70, wherein said in vivo anti-tumor response comprises an in vivo induction of immune effectors that contribute to the rejection of said tumor cell in a patient.

73. (New) The method of claim 70, wherein said in vivo anti-tumor response comprises an in vivo induction of immune effectors that reduce the growth of said tumor cell in a patient.

74. (New) The method of claim 67, wherein said tumor cells are obtained from a primary culture comprising said tumor cell.

75. (New) The method of claim 67, wherein said tumor cells are obtained from an immortal cell line comprising said tumor cell.

76. (New) The method of claim 67, wherein said tumor cells are obtained from a drug sensitive immortal cell line comprising said tumor cell.
77. (New) The method of claim 67, wherein said tumor cells are obtained from an immortal cell line, and wherein said tumor cell comprises at least one tumor associated antigen in common with a tumor of a patient.
78. (New) The method of claim 67, wherein said tumor cells are obtained from a tumor of a patient, and wherein said dendritic cells are isolated from said patient.
79. (New) The method of claim 67, wherein said tumor cells are obtained from a tumor of a patient, and wherein said dendritic cells are isolated from a donor other than the patient.
80. (New) The method of claim 67, wherein said dendritic cells are isolated by in vitro differentiation of dendritic cell precursors isolated from bone marrow, blood or lymph.
81. (New) The method of claim 80, wherein said in vitro differentiation of dendritic cell precursors is effected through the addition of exogenous cytokines to said dendritic cell precursors in vitro.
82. (New) The method of claim 67, wherein said dendritic cells are obtained from a primary culture comprising said dendritic cell.
83. (New) The method of claim 67, wherein said dendritic cells are obtained from an immortal cell line comprising said tumor cell.
84. (New) The method of claim 67, wherein said dendritic cells are obtained from are obtained from a drug sensitive immortal cell line comprising said dendritic cell
85. (New) A method for producing a plurality of dendritic cell/tumor cell hybrids capable of inducing a primary anti-tumor response specific to said tumor cell, wherein the dendritic cell and/or tumor cell is human in origin, said method comprising:
- (i) fusing tumor cells to dendritic cells isolated from bone marrow, blood or lymph to produce a plurality of dendritic cell/tumor cell hybrids, wherein said dendritic cell is not a T-lymphocyte or B-lymphocyte, wherein the dendritic cells and/or the tumor cells are human in origin
 - (ii) selecting for dendritic cell/tumor cell hybrids which express tumor associated cell antigens of said tumor cell in association with an HLA Class II polypeptide, thereby producing a plurality of dendritic cell/tumor cell hybrids capable of inducing a primary anti-tumor response specific to said tumor cell.

86. (New) The method of claim 85, wherein said dendritic cell/tumor cell hybrids express ICAM, and/or B7.
87. (New) The method of claim 85, further comprising culturing said dendritic cell/tumor cell hybrids in vitro with GM-CSF, $\text{TNF}\alpha$, $\text{IFN}\gamma$, or a combination thereof.
88. (New) The method of claim 85, wherein the anti-tumor response specific to said tumor cell is an in vivo anti-tumor response.
89. (New) The method of claim 85, wherein said in vivo anti-tumor response comprises an in vivo induction of immune effectors that confer resistance to a subsequent challenge with said tumor cell.
90. (New) The method of claim 88, wherein said in vivo anti-tumor response comprises an in vivo induction of immune effectors that contribute to the rejection of said tumor cell in a patient.
91. (New) The method of claim 88, wherein said in vivo anti-tumor response comprises an in vivo induction of immune effectors that reduce the growth of said tumor cell in a patient.
92. (New) The method of claim 85, wherein said tumor cells are obtained from a primary culture comprising said tumor cell.
93. (New) The method of claim 85, wherein said tumor cells are obtained from an immortal cell line comprising said tumor cell.
94. (New) The method of claim 85, wherein said tumor cells are obtained from a drug sensitive immortal cell line comprising said tumor cell.
95. (New) The method of claim 85, wherein said tumor cells are obtained from an immortal cell line, and wherein said tumor cell comprises at least one tumor associated antigen in common with a tumor of a patient.
96. (New) The method of claim 85, wherein said tumor cells are obtained from a tumor of a patient, and wherein said dendritic cells are isolated from said patient.
97. (New) The method of claim 85, wherein said tumor cells are obtained from a tumor of a patient, and wherein said dendritic cells are isolated from a donor who is a matched HLA compatible donor.
98. (New) The method of claim 85, wherein said dendritic cells are isolated by in vitro differentiation of dendritic cell precursors isolated from bone marrow, blood or lymph.

99. (New) The method of claim 98, wherein said in vitro differentiation of dendritic cell precursors is effected through the addition of exogenous cytokines to said dendritic cell precursors in vitro.
100. (New) The method of claim 85, wherein said dendritic cells are obtained from a primary culture comprising said dendritic cell.
101. (New) The method of claim 85, wherein said dendritic cells are obtained from an immortal cell line comprising said dendritic cell.
102. (New) The method of claim 85, wherein said dendritic cells are obtained from a drug sensitive immortal cell line comprising said dendritic cell.
103. (New) The method of claim 65 or claim 85, further comprising culturing said dendritic cell/tumor cell hybrids in vitro with GM-CSF.
104. (New) The method of claim 67 or claim 85, further comprising culturing said dendritic cell/tumor cell hybrids in vitro with $\text{TNF}\alpha$.
105. (New) The method of claim 67 or claim 85, further comprising culturing said dendritic cell/tumor cell hybrids in vitro with GM-CSF and $\text{TNF}\alpha$.
106. (New) The method of claim 67 or claim 85, further comprising culturing said dendritic cell/tumor cell hybrids in vitro with $\text{IFN}\gamma$.
107. (New) The method of claim 85, wherein said HLA Class II polypeptide is HLA-DR.
108. (New) The dendritic cell/tumor cell hybrid of claim 85, wherein said HLA class II polypeptide is sufficient to activate naïve T cells.
- 109 (New) The dendritic cell/tumor cell hybrid of claim 67, wherein said MHC class II polypeptide is sufficient to activate naïve T cells.